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Abstract As the most common metastatic disease of abdo-
men pelvic cavity cancer, peritoneal carcinomatosis (PC) ren-
ders significant negative impact on patient survival and qual-
ity of life. Invasive peritoneal exfoliated cancer cells (PECCs)
preferentially select the omentum as a predominant target site
for cancer cell colonization and proliferation compared with
other tissues in the abdominal cavity. The precise pathogenic
mechanism remains to be determined. As omental milky spots
(MSs) are the major implantation site for malignant cells in
peritoneal dissemination, researches on mechanisms of PC
have been mainly focused on MS, primitive lymphoid tissues
with unique structural features, and functional characteristics.
To date, extensive biophysical and biochemical methods have
been manipulated to investigate the MS exact function in the
peritoneal cavity. This review summarized MS as hotbeds for
PECC. The anatomical distribution was briefly described first.
Then, MS histology was systematically reviewed, including
morphological features, cellular constituents, and histological
staining methods. At last, the roles of MS in PC pathological
process were summarized with special emphasis on the dis-
tinct roles of macrophages.
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IHC Immunohistochemistry
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Tumor invasion and metastasis remain the lethal causes of
death and great challenges for cancer patients even after
multimodality clinical treatments. As a regional tumor
In this review, omental milky spots were summarized as hotbeds for
peritoneal cancer metastasis from different aspects as follows:
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progression in abdomen pelvic cavities, peritoneal carcinoma-
tosis (PC) mostly results from carcinomas of the stomach,
colorectum, and ovary [1–5]. Characterized by the implanta-
tion of tumor nodules throughout the peritoneal cavity, PC has
significant negative impacts on patient prognosis because of
refractory ascites, intractable abdominal pain, and progressive
intestinal obstruction. In gastric cancer (GC), almost 60 % of
all causes of GC death is due to PC [6].
Different from hematogenous or lymphatic metastases, the
pathological process of PC involves the following aspects of
peritoneal exfoliated cancer cells (PECCs): adhesion, degra-
dation, migration, angiogenesis, and immune evasion [7–9], in
which gene modification and abundant bioactive compounds
also participate. The precise pathophysiological mechanism
remains unclear. However, increasing studies on PC have
reached a consensus that PECCs specifically choose the omen-
tum as the implantation site [10–13]. Macroscopically, the an-
atomical particularity of omentum consists in its positional
adjacency to abdominal primary tumors. As the central regu-
lator of peritoneal homeostasis, the omentum also performs
active functions in regulating fluid and solute transport and
promoting angiogenesis [14]. Once PC occurs within the
omentum, malignant cells transported by peritoneal fluids tend
to colonize and proliferate these surrounding neo-vessels. It
has been well recognized that tumor invasion and metastasis
are closely associated with the coevolution of cancer cells and
tumor microenvironment [15–17]. On the basis of defined
Binvasion unit^ by Fang et al. [18], the Bpulse-mode^ of cancer
invasion and metastasis provides a new insight for cancer re-
searches. Similarly in the omentum, there are numerous tiny
functional units called milky spots (MSs), serving as suitable
microenvironment for PECC [10, 19].
MSs were firstly observed as dense corpuscles resem-
bling cotton wool in the omentum and pleura of rabbits in
1863 by Recklinghausen [20]. In 1874, Ranvier confirmed
this discovery and named these corpuscles milky spots
[21]. Since Hagiwara reported omental MS as the major
implantation site for malignant cells in peritoneal dissem-
ination in mice in 1993 [10], researchers have gradually
noticed the relevance between MS and PC. Due to the diffi-
culty of locating human MS with the naked eye, few re-
searches had been dedicated to them until the 1990s. In the
beginning, some researchers considered MS as lymphatic
structures [22], whereas others regarded them as suppliers of
peritoneal macrophages [23, 24]. In 2009, Rangel-Moreno et
al. [25] provided compelling data to confirm MS as unique
secondary lymphoid organs, which was also reported soon
afterwards by Mebius [26]. To date, extensive biophysical
and biochemical methods have been manipulated to detect
and unravelMS unique structural features and functional char-
acteristics. On the basis of previous work, the anatomical dis-
tribution, histological features, and roles in PC progression of
MS have been systematically summarized in this review.
Anatomical distribution of MS
Pleural and peritoneal cavities are repositories of MS [27]. In
pleural cavity, MSs seem to be located mainly in the pleural fold
behind the pericardium rather than lung parenchyma [27].
However, MS can be found in many tissues in abdomen pelvic
cavities. Using P388 leukemia cells labeled with
bromodeoxyuridine for i.p. injection of mice, Hagiwara et al.
[10] established the descending order of tissue MS content as
omentum, gonadal fat, mesenterium, posterior abdominal wall,
stomach, liver, intestine, anterior abdominal wall, and lung.
Except for it, there are still no straightforward researches on
quantitative comparisons of pleural and peritoneal MS.
Subsequent studies applying peritoneal metastatic models
also revealed that the omentum is a predominant site [12, 13,
28–30] for MS distribution. Additionally, Sorensen et al. [12]
uniquely utilized an in vivo imaging system (IVIS) for closer
microscopic analysis of green fluorescent protein (GFP) ex-
pressing B16 tumor cells injected i.p. and found that the tumor
foci were localized to distinct areas coinciding with MS zones
on the omentum.
In addition, Imai et al. [31] classified MS as type I (farther
type) and type II (closer type) based on MS location relation-
ship with blood vessels. However, recent studies using whole
mount technique of the omentum had found that MS tended to
distribute along a dense network of blood vessels [30].
Histological features of MS
Gross morphology and size
MSs with opaque patch shape [32] are similar in morphology
(round or oval), while different in sizes, with diameters rang-
ing from 349 to 756 μm [33]. MS densities decrease with age
in the human omentum [32, 33], ranging from 40–50/cm2 in
neonates to less than 10/cm2 in humans 70 years of age.
In our experiments, hematoxylin and eosin (H&E) staining
method was manipulated to study 200 MS slides obtained
from the omentum specimens of gastric cancer and rectal can-
cer patients. These slides were examined under Olympus
BX51 microscope equipped with an Olympus DP72 camera
(Olympus Optical Co., Ltd., Tokyo, Japan) at 100, 200, and
×400 magnifications, and the images were captured by DP72
camera. Then, we drew the outline of every MS images under
the guide of expert pathologist. The morphological features of
MS were shown as different shapes with corresponding pro-
portions (Fig. 1i). A self-adaptive Otsu threshold method [34]
was adopted to convert the obtained images into binary im-
ages (Fig. 1g, h). Then, the perimeter of MS region could be
output as pixel value spontaneously. Shapes of MS were
mainly round, oval, and irregular form in the adipose and
perivascular annular (Fig. 1). The median MS perimeter was
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2752 (range 817∼7753) computer-based pixels. Considering
125 pixels were equal to 20 μm in these images at ×400
magnification, the median MS diameter of our results was
about 140.2 (41.6–395.1) μm.
Cellular constituents
Recent researches demonstrate that MSs are small specific
structures devoid of capsule, formed between 20th and 35th
week of gestation [32], consisting of macrophages, lympho-
cytes, and some plasma cells supplied by blood and lymphatic
vessels [35–37].
In the omentum, abundant immunocytes aggregate in the
perivascular region to constitute MS (Fig. 2). At the micro-
scopic level, MSs contain a glomerular-like capillary network
of blood vessels which enables fluid exchange between the
peritoneal cavity, the blood stream, and the surrounding
omental tissue [38, 39]. Diameters of macrophages with
irregular shape vary from 15 to 20 μm. Diameters of both B
and T lymphocytes vary from 7 to 10 μm [33].
The above cellular compositions are arranged around
the omental glomeruli that lie directly beneath the discon-
tinuous mesothelium layer [23], which are characterized
by the presence of pores or stomata, allowing for direct
communication with the peritoneal cavity [40]. Typically
under the scanning electron microscopy, macrophages of
activated MS were found to change their membrane activ-
ity prominently and migrate through the intercellular sto-
mata of MS mesothelial cells into the peritoneal cavity
[41–43].
Cellular percentage and distribution
For different experimental subjects and different states of
the greater omentum, percentages of MS cellular constitu-
ents also differed to some extent, such as macrophages, T
lymphocytes, and B lymphocytes (Table 1). As few
Fig. 1 H&E staining of milky spots. The yellow frame is used to show
the gross morphology of MS. a Round. b Oval. c Irregular form in
adipose tissues. d Perivascular annular. e Perivascular aggregation. f
Clostridial form. g, h Computer methods were used to convert HE
images into binary images for the calculation of MS perimeter. i
Proportions of MS shapes (a–h ×400, scale bar= 20 μm)
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authors recently had tried to update the cellular knowledge
of MS, we conducted immunohistochemical study to
quantitatively analyze MS cellular constituents. For the
demonstration of macrophages, T lymphocytes and B lym-
phocytes, the indirect avidin-biotin-peroxidase technique
with the monoclonal antibodies PG-M1, F7.2.38, and
L26 (DAKO, Denmark) was used. These antibodies
distinguish the human leukocyte differentiation antigens
CD68, CD3, and CD20cy, respectively. Our results are
also shown in Table 1 and Fig. 3.
Previous researches indicated that macrophages and lym-
phocytes did not show any preferential pattern of distribution
in the MS [23, 33]. However, macrophage precursors were
centrally localized inside the MS, while more differentiated
cells were found in peripheral areas [24]. Referring to our
immunohistochemistry (IHC) studies of MS, macrophages
preferentially distributed diffusely, while lymphocytes were
located intensively in a particular position, and the areas of
T lymphocytes seemed to be roughly complementary with B
lymphocytes (Fig. 3b, c).
Histological staining methods
MS can be observed with the naked eye only by experts in
perivascular fatty tissue of the omentum. Therefore, they are
more often stained both in vivo and in vitro for easier obser-
vation at the microscopic level. Since macrophages in MS can
engulf the carbon or ink particles into their cytoplasm, re-
searchers in the beginning injected active carbon [10, 44–46]
or black ink [42] into the serous cavities of live animals to
facilitate the detection and observation, showing MS as tiny
black dots after about 20 min. In addition, macrophages and T
lymphocytes located in the milky spots were coloring dark red
by nonspecific esterase stain [10].
Conventional H&E and Giemsa methods are also applied
to stain MS internal immune cells. Collins et al. [39] showed
that the surface mesothelium layer of human MS was loosely
arranged without basement membrane, and macrophages
were occasionally found among the neighboring mesothelial
cells. Capillaries with high density and different levels consti-
tuted the basic skeleton of MS within the internal layer. Other
H&E staining researches [11, 27, 42, 46, 47] found similar
results that these purple cellular clusters stained by hematox-
ylin constitute MS together with pink blood vessels stained by
eosin. However, immune cells could not be differentiated into
specific types for further studies only by H&E staining.
Fig. 2 Structure of milky spots. MSs are small specific structures
composed of macrophages, lymphocytes, and some plasma cells that
aggregate in the perivascular region
Table 1 Different results of milky spot cellular percentages
Authors Year Studying model States of the omentum Macrophages T lymphocytes B lymphocytes
Beelen H et al. [42] 1988 Male Wistar rats Cell suspensions; acute inflammatory
state
30.0 % 20.0 % 10.0 %
Shimotsuma et al. [31] 1991 8-month-old infants
with neuroblastoma
Normal 47.5 % 11.7 % 29.1 %
Krist LF et al. [23] 1995 Male patients Without intra-abdominal infection
or malignancy
67.9 % 10.2 % 10.1 %
Liu et al. 2015 Gastric patients and
rectal patients
Normal 12.4 % 46.1 % 28.4 %
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Therefore, IHC/immunocytochemistry methods [11, 12, 24,
30, 32, 33, 48, 49] were applied using homologous monoclo-
nal antibodies for the different leukocyte superficial differen-
tial antigens of MS cellular compositions. On the basis of
traditional IHC methods, immunofluorescence staining [30,
50] featured by the fluorescence of GFP-tagged immune cells
turned out to be more obvious for the detection of MS
macrophages.
To date, extensive biophysical and biochemical stain-
ing methods have been used to detect MS (Table 2).
However, nearly all researches failed to obtain in situ
quantitative information with morphological features for
multiple cellular constituents of MS except for Gerber et
al. [30], who succeeded in staining simultaneously with
anti-CD45 to label immune cells (red), anti-CD31 to mark
blood vessels (green), and anti-LYVE-1 (yellow) to iden-
tify lymphatic vessels.
Physiological functions of MS
The omentum is characterized by a single layer of mesothelial
cells and a submesothelial region composed of connective
tissue with a few fibroblasts, mast cells, macrophages, and
blood vessels [51]. As the central regulator of peritoneal ho-
meostasis, the omentum performs active functions in regulat-
ing fluid and solute transport, sensing and repairing injuries,
promoting angiogenesis, fighting infection, providing stem
cells, producing regulatorymolecules, and storing and supply-
ing lipids [14]. TheMS cellular compositions can be classified
into structural, migratory, and functional elements.
Fibroblasts, adipocytes, mesothelia, and endothelia compose
the structural elements. Lymphocytes, granulocytes, and
monocytes make up the migratory elements. The functional
element is comprised of macrophages, stromal cells, and high
endothelium of the veins [52].
Fig. 3 IHC staining of milky spots to analyze the cellular percentages. a
Procedures of IHC study. bCellular composition of human milky spots. c
Macrophages are diffusely distributed within MS. d+ e Lymphocytes are
located intensively in a particular position. The location of T lymphocytes
is roughly complementary with B lymphocytes, as shown by the yellow
frame (c1–e1 ×200; scale bar= 50 μm; c2–e2; ×400; scale bar= 20 μm)
Tumor Biol. (2016) 37:5715–5726 5719
Secondary lymphoid organs in the omentum
As mentioned above, MSs were identified as high densities of
immune cells located atop densities of capillaries within the
surrounding adipocytes fromH&E stained images [11, 27, 39,
42, 47, 49]. A glomerular-like capillary network within MS
enables fluid exchange between the peritoneal cavity, the
bloodstream, and the surrounding omental tissue [39].
Immunocytes in MS play an important role in peritoneal im-
munity. Omental MS and macrophages could be activated by
i.p. injection of a streptococcal preparation, OK-432 [41]. The
activated macrophages demonstrate marked surface mem-
brane activity and migration capability and participate in peri-
toneal immunoreactions against foreign matters. Ultimately,
the structural integrity of MS was partially lost by the injected
streptococcal preparation [41] or tumor cells [30].
For long it has been controversial as to whether to regard
MS as secondary lymphoid organs for their lack of dendritic
cells as well as follicular dendritic cells compared with con-
ventional lymphoid organs. However, compelling data pro-
vided by Rangel-Moreno et al. [25] terminated the debated
the classification above. Using splenectomized lymphotoxin-
alpha-deficient mice (Lta-/-), which already lacked lymph
nodes and Peyer’s patches, they creatively designed SLPmice
model by reconstituting Lta-/-with wild-type bonemarrow. As
summarized by Mebius [26] later, antigens injected into the
peritoneal cavity of SLP mice were shown to accumulate in
MS, resulting in the generation of antigen-specific antibodies.
Germinal center B cell responses and proliferation of Tcells in
response to intraperitoneally injected antigens could also be
observed in MS. Although develop in the absence of lym-
phoid tissue inducer cells, MSs function as unique secondary
lymphoid organs that promote immunity to peritoneal
antigens.
Suppliers of peritoneal macrophages
MSs are also considered as the site for the generation and
differentiation of peritoneal macrophages [24, 41, 53–55].
Based on ultrastructural endogenous peroxidase cytochemis-
try using a panel of monoclonal antibodies that recognize
precursor cells antigens in the MS, the precursors of
Table 2 Histological staining methods for observing milky spots
Staining methods Researches Year Studying model Stained content of MS Result
Toluidine-blue staining Shimotsuma et al.[31] 1991 Infants Mast cells Purple
Activated carbon Clark et al. [44] 2013 Mouse MS, macrophages Black
Di Paolo et al. [48] 2005 Mouse
Hagiwara et al. [10] 1993 Mouse
Shimotsuma et al. [43] 1989 Mouse
India ink Krishnan et al. [40] 2012 Mouse MS, blood vessels Black
H&E staining Clark et al. [44] 2013 Mouse Immune cells Purple
Krishnan et al. [40] 2012 Mouse
Panasco et al. [25] 2010 Mouse
Khan et al. [11] 2010 Mouse
Abe et al. [45] 2009 Mouse
Collins et al. [37] 2009 Human MS Purple cellular clusters
Nonspecific esterase stain Hagiwara et al. [10] 1993 Mouse Macrophages, T lymphocytes Dark red
Giemsa staining Clark et al. [44] 2013 Mouse Immune cells Dark staining areas
Panasco et al. [25] 2010 Mouse
Immunohisto-/cyto-chemistry Sedlacek et al. [46] 2013 Mouse Immune cells With reference to the
original literatureKhan et al. [11] 2010 Mouse
Sorensen et al. [12] 2009 Mouse
Gerber et al. [28] 2006 Mouse
Krist et al. [30] 1997 Infants
Shimotsuma et al. [31] 1991 Infants
Wijffels et al. [24] 1992 Mouse
Beelen et al. [42] 1988 Mouse
Immunofluorescence staining Oosterling et al. [47] 2006 Mouse Macrophages Green
Gerber et al. [28] 2006 Mouse GFP-tagged immune cells Green
Infiltrated tumor cells Tsujimoto et al. [19] 1996 Mouse Melanoma cells Black
GFP green fluorescent protein
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macrophages were identified as from the mononuclear phago-
cyte system (MPS) [24]. As precursor cells differentiated, de-
veloping MS contained macrophages in the different stages of
maturation during the 20th to 35th weeks of gestation [32].
These peritoneal macrophages participate in the absorption
and clearance of bacteria and debris from the peritoneal cavity
[41] and act as the frontier line of immune defense along with
MS surface mesothelium.
Pathological reaction of MS
Inflammatory reaction
Although the omentum is not inherently motile, experimental
models have shown that, in response to foreign matters or
inflammation, omental blood flow increases, and the propor-
tion of MS expands. In inflammatory conditions, MS can
provide immunocytes expressing stem cell markers [56, 57]
as well as inflammatory, hemostatic, and chemotactic sub-
stances [58] such as vascular endothelial growth factor
(VEGF) and basic fibroblast growth factor (bFGF) [59].
These activated cells accumulate to injured sites [60] and pro-
mote the recruitment of inflammatory cells [41] within the
peritoneal cavity, thus speeding tissue repair and regeneration.
During the delayed reaction period, macrophage cytoplasms
increase and travel through the MS stomata into the peritoneal
cavity to limit inflammation [41, 43].
Insufficient antitumor effect of MS
Dual-functioning roles of tumor-associated macrophages
in MS
On the one hand, omental MSs are cytotoxic against PECC to
show tumor-resistant effect; on the other hand, they become a
highly efficient Bnatural filter^ for screening cancer stem cells
[13, 61], thus providing a microenvironment in which cancer
cells niche in this region to form a metastatic foci [12, 31, 62].
This phenomenon owes largely to the distinct roles of tumor-
associated macrophages, which respond to the presence of
stimuli in the different parts of tumors with the release of a
distinct repertoire of growth factors, cytokines, chemokines,
and enzymes that regulate tumor growth, angiogenesis, inva-
sion, and metastasis [63].
Throughout the life span of PECC within MS, from
early-stage tumor micro-metastatic foci that are beginning
to vascularize to late-stage tumors that PC occurs, mono-
cytes migrate through blood vessels into MS region under
the influence of tumor-derived chemoattractants, including
colony-stimulating factor-1 (CSF-1/M-CSF), the CC
chemokines, and VEGF [64]. Then they continually prolif-
erate and differentiate into tumor-associated macrophages
(TAMs), which typically have been categorized by the di-
chotomy of classical (M1) and alternative (M2) statuses
[65]. M1 are described as pro-inflammatory with tumor-
resistant effects. In contrast, M2 are associated with immu-
nosuppression, modifications of extracellular matrix
(ECM), and promotion of tumor angiogenesis and metas-
tasis [66–68]. During tumor progression, TAMs have a
remarkable degree of plasticity for undergoing phenotypic
switch from M1 to M2 [69]. In different microenviron-
ments, TAMs act distinctly to promote cancer cell motility
in the areas of invasion, to promote metastasis in stromal
and perivascular areas, and to stimulate angiogenesis in
avascular and perinecrotic hypoxic areas [63].
Peritoneal mesothelial cells and MS macrophages consti-
tute the first line of defense in the peritoneum. However,
PECC can attach to the peritoneum either by the surface of
mesothelial cells or the exposed ECM. The attachment of
PECC to mesothelial monolayers is mediated by different ad-
hesion molecules like intercellular cell adhesion molecule-1
(ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1)
[70–72]. Attachment of PECC to the ECM is mainly mediated
by integrin [73, 74]. On one hand, the structure and function of
mesothelial cells play roles in resisting the adhesion and col-
onization of PECC [75]. On the other hand, mesothelial cells
possess both epithelial and mesenchymal characteristics and
readily undergo epithelial-mesenchymal transformation
(EMT) and myofibroblast transformation in response to apo-
ptosis and fibrosis induced by both PECC and TAMs [76, 77].
A TAM-induced HPMC injury model [77] indicated that
TAMs directly enhance the invasive ability of PECC and
further degrade the integrity of mesothelial cells, enhanc-
ing the opportunity for PECC adhesion and colonization.
Once injured, the adjacent mesothelial cells will be
changed into a cuboidal morphology, and the underlying
ECM will be exposed to PECC invasion. The fibroblasts
are probably the most abhorrent elements of ECM.
Activated by TGFβ-1 signaling, cancer-associated fibro-
blasts (CAFs) play roles in promoting cancer growth, ad-
hesion, and invasion [78–80]. As collaborative assistants
and along with mesothelial cells and ECM, MS TAMs can
provide a favorable environment for PECC invasion.
Milky spots: a hypoxic niche for peritoneal cancer
It is widely accepted that the growth and spread of cancer cells
require angiogenesis, a process by which neo-vessels sprout
from the existing vasculature. There are hypoxic areas in meta-
static foci ofMS because neo-vessels are disorganized and prone
to collapse. TAMs accumulate in such hypoxic areas and upreg-
ulate VEGF and other proangiogenic factors [81], such as TNF-
a, IL-8, and bFGF. Additionally, TAMs also synthesize the ele-
vated levels ofMMP-7 [82], which can stimulate endothelial cell
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proliferation and migration to support tumor angiogenesis [83],
thus providing energy for tumor cell proliferation.
Recent researchers have also observed a positive correlation
between hypoxic microenvironment and PC and revealed
hypoxia-inducible factor-1α (HIF-1α) expression in MS as a
predominant factor [84] that controls the tumor stem cell phe-
notype. As mentioned above, MS could only eliminate mature
tumor cells rather than tumor stem/progenitor cells [13, 61]. As
a subunit of HIFs regulated by oxygen levels, HIF-1α can
trigger a set of adaptive transcriptional responses to regulate
tumor stem cell differentiation and self-renewal [85, 86]. On
one hand, stem cell-related protein expression is correlated
with HIF-1α overexpression. Tumor stem cells’ self-renew is
enhanced by hypoxia through HIF-1α, but their differentiation
ability is reduced [84], thus leading to the accumulations of
abundant tumor stem cells in MS hypoxic areas and ultimately
promoting a more aggressive tumor phenotype. On the other
hand, epithelial-mesenchymal transition could be induced by
hypoxia through HIF-1α, thus enhancing PC occurrence ratio
and indicating a negative prognosis for cancer patients.
Fig. 4 Interactions between PECC and MS cellular constituents. a
Adhesion of PECC onto mesothelial cells or through the MS stomata. b
Dual-functioning roles of TAMs in MS. Monocytes migrate through the
blood vessels into MS region under the influence of tumor-derived
chemokines and continually differentiate into TAMs, including M1 and
M2 macrophages. M1 are pro-inflammatory with tumor-inhibiting
effects, while M2 favor tumor growth and metastasis. c Apoptosis and
fibrosis of mesothelial cells by both PECC and M2 macrophages. d
Tumor angiogenesis within MS. VEGF is the most important factor to
promote proliferation and migration of endothelial cells. e Formation of
micro-metastasis within MS before PC occurs
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Tumor promotion effect of adipocytes surrounding MS
As is known, the majority of the omentum is composed of
bands of adipose tissue that mainly contain adipocytes [87].
In general, the well-known functions of adipocytes include
lipid storage, production of endocrine molecules [88, 89],
and serving as an integrating hub for inflammation, metabo-
lism, and immunity [46]. However, the roles of adipocytes to
promote homing, migration, and invasion of cancer cells were
first reported by Nieman et al. [90]. In their co-culture model
of ovarian cancer cells and adipocytes, the lipolysis of adipo-
cytes and β-oxidation in cancer cells indicated that adipocytes
could act as an energy source for cancer cells. Clark et al. [46]
developed this finding into a two-step model for omental col-
onization mediated by both omental MS and adipocytes. The
first step for the adhesion and localization of PECC is depen-
dent on MS. Then adipocytes provide fatty acids for rapid
proliferation and tumor growth, thus promoting subsequent
spread of PECC to other sites. Therefore, MS and adipocytes
play distinct and complementary roles in PECC metastatic
colonization within peritoneal cavity.
Relationships between MS and PC
Primary tumors of the omentum are rare; however, it is the
most favorite site of peritoneal metastasis for cancers of the
stomach, colorectum, and ovary. Invasive cancer cells exfoli-
ate from primary tumors, transfer through peritoneal fluid or
ascites [91, 92], and preferentially attach the peritoneum, pre-
dominantly the greater omentum. Some differences do exist in
the pattern or mechanism of MS-related PC from different
primary tumors. The omentum is a fatty tissue that connects
the spleen, stomach, pancreas, and colon [93]. Owing to
positional adjacency to the omentum and the existence of
gravity, the anatomical particularity of stomach/colon
makes it much easier for cancer cells from gastrointestinal
system to undergo implantation metastasis. Except for the
above straightway metastatic route, gastric cancer cells
and colorectal cancer cells could also be transported by
peritoneal fluid [94]. However, ovarian cancer cells have
access to and can potentially lodge within the omental MS
only through the peritoneal fluid [95]. Although PECCs
from different origins demonstrate diversities during the
early step of peritoneal metastasis, PECCs have all expe-
rienced the following aspects in the process: adhesion,
degradation, migration, angiogenesis, and immune eva-
sion [7–9].
The peritoneum is comprised of a single layer of mesothe-
lial cells and its associated underlying ECM [96]. The meso-
thelium is inevitably damaged after interactions with PECC,
particularly for PC patients having surgical trauma and stress
[97]. Then, exposed MSs lying beneath the mesothelium ac-
tively take over the mission to fight against PECC. The MS-
driven model attributing to the peritoneal dissemination of
different tumor cells (melanoma cells, ovarian cancer cells,
colon cancer cells, etc.) is based on a large body of in vivo
data showing that tumor cells rapidly and specifically attach,
invade, and proliferate within MS after intraperitoneal injec-
tion [12, 30, 42, 46, 49, 50, 61]. For example, ovarian cancer
cells rapidly localize to the mice omentum within minutes
after intraperitoneal injection [10, 11, 28]. For different exper-
imental models or detection methods, the earliest occurrence
time of PECC infiltration within MS varies from hours [50,
61] to days [30, 42]. However, infiltrated PECCs from gastro-
intestinal or gynecological cancer undergo similar temporal
dynamics before apparent tumor nodules proliferate in the
omentum. Herein, cancer immunoediting theory by Duun
GP et al. [9] is recommended to explain the three stages of
interplay between PECCs and MSs. In the beginning, both
sides are influenced by each other and to some extent well
prepared for the Bbattle^ of occupyingMS areas. In the second
stage, the number of total immune cells in MS increases in
accordance with the visual enlargement of MS size. Mainly
due to the cytotoxic abilities of macrophages mentioned
above, numbers of PECC decline gradually prior to next stage.
However, the screened cancer stem/progenitor cells retain the
potency to proliferate and differentiate after the apoptosis of
mature cancer cells [13, 61]. Ultimately, proliferating cancer
cells inMS areas formmicro-metastasis, whereas the structure
of MS is disrupted leaving segmented even sporadic immune
cells within the tumor mass [30].
Therefore, resident immune cells in MS are not able to
prevent tumor growth [28, 50]; instead, pro-inflammatory
cytokines secreted from cancer, stromal, mesothelial, and
immune cells, particularly macrophages, contribute to an
inflammatory environment that promotes peritoneal metas-
tasis [98–100]. Furthermore, a large number of adipocytes
surrounding MS may promote the growth of the attaching
cancer cells by providing lipids to meet their energy de-
mands [90]. The impact of MS on peritoneal metastasis is
profound and transforms the initial pattern of micro-
metastatic foci into a widespread peritoneal carcinomatosis
[101, 102]. Based on current understanding, the involve-
ment of MS in peritoneal carcinomatosis formation could
be summarized in Fig. 4.
Conclusions
With expanding knowledge in the fields of MSmorphological
and functional studies, these tiny functional units located pre-
dominantly within human omentum have been turned out to
be hotbeds for peritoneal exfoliated cancer cells. In-depth
knowledge and renewing concepts of MS contribute to under-
standing the multistage development of PC.
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